Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Michael Rhodes

Premium

Michael Rhodes has left Life Technologies to join NanoString Technologies. At NanoString, Rhodes will be the director of collaboration and applications development and focus on digital gene expression technologies.

Rhodes held various positions at Life Tech, including most recently senior manager of the sequencing portfolio. He joined Applied Biosystems in 1999 in the genetic analysis division before the company merged with Invitrogen and became Life Tech.

In his new position, Rhodes will report to Joe Beechem, who also recently came to NanoString from Life Tech, where he was most recently vice president, head of advanced sequencing and head of global sequencing chemistry, biochemistry, and biophysics.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.